AVEO to raise $61 million through personal placement AVEO Pharmaceuticals, Inc follow this site . , a biopharmaceutical business focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase contract with a select group of institutional and accredited investors providing for a private placement, or PIPE financing. Upon the closing of the PIPE financing, AVEO will receive gross proceeds of around $61 million resulting from the sale of 4.5 million shares of common stock at a price of $13.50 per share, which represents an approximate 7 percent low cost to the closing price on October 28, 2010. The closing of the PIPE funding is subject to standard closing conditions. J.P. Morgan Securities LLC and Canaccord Genuity Inc.
Related StoriesCopley Scientific to showcase new accessories at RDD Europe 2015Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanInnovation in anaesthesia: an interview with Matti Lehtonen, GE Healthcare The pharmaceutical sector is one of the fastest-growing marketplaces for automated making solutions and ATS is certainly rapidly becoming the 1st choice in automation, stated Klaus Woerner, Chief and President Executive Officer of ATS. This order is certainly strategically significant for all of us because it’s in the field of drug delivery gadgets, a rapidly developing region within pharma and it’s for a long-term client – one of the world’s largest pharmaceutical companies. This consumer has once again shown its self-confidence in ATS by awarding us this essential high profile project in one of their essential operating divisions.